We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ADVFN Financial News : Breaking financial news, market insights, commentary & economic analysis from the world stock markets.
60 Degrees Pharma Shares Rise 18% After Type C Meeting With FDABy Chris Wack 60 Degrees Pharmaceuticals shares were up 18% to 74 cents after the company said it will move forward with a pivotal clinical study of tafenoquine in hospitalized babesiosis patients in the U.S. following a Type C meeting with the Food and... |
Alphabet on Track for Highest Close Since February 2022 -- Data TalkAlphabet Inc. Class A (GOOGL) is currently at $147.82, up $1.44 or 0.98% --Would be highest close since Feb. 2, 2022, when it closed at $148.00 --Currently up three consecutive days; up 4.49% over this period --Best three day stretch since the three days... |
Trending: Exxon Sues 2 Investment Firms Over Shareholder Proposal9:57 ET -- Exxon Mobil is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Exxon is suing two sustainable investment firms in a bid to block them from putting forward a shareholder... |
Gilead Down Over 10%, on Pace for Largest Percent Decrease Since December 2014 --..Gilead Sciences, Inc. (GILD) is currently at $78.06, down $9.23 or 10.57% --Would be lowest close since Dec. 7, 2023, when it closed at $78.05 --On pace for largest percent decrease since Dec. 22, 2014, when it fell 14.34% --Currently down three of the... |
60 Degrees Pharma Plans Tafenoquine Study After FDA MeetingBy Chris Wack 60 Degrees Pharmaceuticals said that following a Type C meeting held Wednesday with the Food and Drug Administration, it will move forward with a pivotal clinical study of tafenoquine in hospitalized babesiosis patients in the U.S. In advance... |
Correction to Gilead Says Trodelvy Trial Didn't Meet Primary Endpoint ArticleGilead agreed in 2020 to buy Trodelvy-maker Immunomedics for $21 billion. "Gilead Says Trodelvy Lung Cancer Trial Didn't Meet Primary Endpoint" at 8:47 a.m. ET incorrectly said Gilead agreed in 2022 to buy Immunomedics. (END) Dow Jones... |
News Highlights: Top Company News of the Day - Monday at 9 AM ETSunoco to Buy NuStar Energy in $7.3 Billion Deal Fuel distributor Sunoco has agreed to buy liquids terminal and pipeline operator NuStar Energy in a stock-swap transaction valued at about $7.3 billion, including assumed debt. WeWork Wrestles to Amend... |
Bayer Names Nelson Ambrogio as New Head of Radiology BusinessBy Mauro Orru Bayer appointed Nelson Ambrogio as head of the radiology business under its pharmaceuticals division, succeeding Gerd Krueger who will retire after eight years at the helm of the business. The German pharmaceutical and agricultural... |
Gilead Says Trodelvy Lung Cancer Trial Didn't Meet Primary EndpointBy Will Feuer Gilead Sciences said a Phase 3 trial testing Trodelvy in certain lung cancer patients failed to improve overall survival, results that sent shares sharply lower. Gilead agreed in 2022 to buy Trodelvy-maker Immunomedics for $21 billion. In the... |
News Highlights: Top Company News of the Day - Monday at 9 AM ETSunoco to Buy NuStar Energy in $7.3 Billion Deal Fuel distributor Sunoco has agreed to buy liquids terminal and pipeline operator NuStar Energy in a stock-swap transaction valued at about $7.3 billion, including assumed debt. WeWork Wrestles to Amend... |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions